Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
Background.Treatment options of recurrent malignant gliomas are very limited and with a poor survival dozy dinkum moppet benefit.The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial.Patients and methods.The medical documentation of 19 adult patients with recurrent malignant gliomas was retrospect